U.S. stock market intraday update: Sarepta Therapeutics up 9.35%

U.S. Stock Market Midday Update Sarepta Therapeutics, up 9.35%, with increased trading volume. Based on recent key news: On July 25, Sarepta resumed trading, and the stock price turned upward. On July 25, the FDA required Sarepta to conduct more clinical trials to confirm the safety of Elevidys, leading to a significant drop in stock price. On July 28, Barclays downgraded Sarepta's rating to "underweight" due to regulatory updates on Elevidys. Stocks with High Trading Volume in the Industry Celcuity, up 175.19%, with a trading volume of $749 million. Based on recent important news: On July 28, Celcuity announced that its three-drug combination therapy outperformed AstraZeneca's treatment in breast cancer trials, significantly reducing the risk of disease progression or death by 76%, driving the stock price up. On July 28, Celcuity reported significant improvements in the primary endpoint of the PIK3CA wild-type cohort in the VIKTORIA-1 trial, planning to submit a new drug application to the FDA in Q4 2025, enhancing market confidence. On July 25, Celcuity launched the VIKTORIA-2 clinical trial, with the first patient already receiving treatment, showing the company's positive progress in breast cancer treatment, boosting investor sentiment. Gilead Sciences, down 2.47%, with a trading volume of $176 million. Based on recent key news: On July 25, EU regulators supported Gilead's biannual injection prevention plan for AIDS, causing the stock price to rise by 2.31%. On July 26, Needham upgraded Gilead's rating to "buy," with a target price of $133, leading to a 2.75% increase in stock price. On July 27, market analysts suggested that Gilead is not the best investment choice currently, resulting in a decline in stock price. Forte Biosciences, down 0.47%, with increased trading volume. Based on recent key news: On July 27, a retail investor frenzy led to a surge in trading volume for small-cap stocks, affecting Forte Biosciences and increasing stock price volatility. On July 28, increased market attention on biotech stocks impacted Forte Biosciences due to its industry position. On July 25, the company announced an increase in quarterly dividends, demonstrating a commitment to shareholder returns, but failed to boost the stock price. Stocks with High Market Capitalization in the Industry AbbVie, down 0.42%, with increased trading volume. Based on recent important news: On July 28, AbbVie's cancer drug Rova-T faced clinical failure, shifting reliance to Skyrizi and Rinvoq for growth. Despite solid financials, market confidence in its future growth was affected, leading to a 0.42% decline in stock price On July 26, analysts noted that AbbVie was not on the recommended list. Although rated as a moderate buy, other stocks were considered to have greater investment value, leading to weakened investor confidence. On July 25, there was an increased preference in the market for high-dividend stocks. As a dividend king, AbbVie, despite its high dividend yield, failed to attract sufficient buying interest, putting pressure on its stock price